CJ Bioscience Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
311690
- Investments
-
2
- Share Price
-
$2.66
- (As of Friday Closing)
CJ Bioscience General Information
Description
CJ Bioscience Inc is engaged in directing a healthy life based on microbiological research. It presents directions and solutions to all fields of research on the microbiome, such as academia in the bioinformatics field, R&D centers of hospitals and research institutes, and NGS (next-generation sequencing) service companies. Its services includes NGS, EZBioCloud, Healthcare among others.
Contact Information
Website
www.cjbioscience.comCorporate Office
- 7th Floor, Grand Central B, 14 Sejong-daero
- Jung-gu
- Seoul, 04527
- South Korea
Corporate Office
- 7th Floor, Grand Central B, 14 Sejong-daero
- Jung-gu
- Seoul, 04527
- South Korea
CJ Bioscience Timeline
CJ Bioscience Stock Performance
As of 13-Nov-2026, CJ Bioscience’s stock price is $2.66. Its current market cap is $34.8M with 13.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.66 | $2.62 | $2.12 - $6.90 | $34.8M | 13.1M | 6.8K | -$1.18 |
CJ Bioscience Financials Summary
As of 30-Jun-2026, CJ Bioscience has a trailing 12-month revenue of $2.53M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 15,196 | 51,591 | 66,530 | |
| Revenue | 2,534 | 2,595 | 2,541 | 4,264 |
| EBITDA | (12,750) | (15,028) | (21,872) | (13,930) |
| Net Income | (15,385) | (16,868) | (24,067) | (17,525) |
| Total Assets | 39,137 | 50,234 | 67,625 | 70,715 |
| Total Debt | 5,108 | 7,230 | 6,348 | 6,622 |
CJ Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CJ Bioscience Comparisons
Industry
Financing
Details
CJ Bioscience Competitors (36)
One of CJ Bioscience’s 36 competitors is Shanghai Medicilon, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Shanghai Medicilon | Formerly VC-backed | Shanghai, China | ||||
| GenScript | Formerly VC-backed | Nanjing, China | ||||
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| Eurofins Genomics Americas | Corporation | Louisville, KY | ||||
| Pharmaron | Formerly VC-backed | Beijing, China |
CJ Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CJ Bioscience Patents
CJ Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022065957-A1 | Composition for diagnosis or treatment of inflammatory diseases, comprising microorganism | Inactive | 28-Sep-2020 | ||
| WO-2021256860-A1 | Apparatus for determining intestinal microbiome index, method therefor, and recording medium recording instruction therefor | Inactive | 16-Jun-2020 | ||
| WO-2021162457-A1 | Anticancer therapy using faecalibacterium sp. microorganism | Inactive | 10-Feb-2020 | ||
| WO-2020251249-A1 | Method for detecting dysbiosis of infant | Inactive | 11-Jun-2019 | ||
| WO-2020197362-A1 | Faecalibacterium sp. microbe and anticancer composition comprising same | Inactive | 28-Mar-2019 | C12N1/20 |
CJ Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CJ Bioscience Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CJ Bioscience Investments (2)
CJ Bioscience’s most recent deal was a Corporate Asset Purchase with 4D Pharma (15 Microbiome Drug Pipelines in Leeds, United Kingdom). The deal was made on 04-May-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 4D Pharma (15 Microbiome Drug Pipelines in Leeds, United Kingdom) | 04-May-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Seungwoon Baek (Production and Research Facilities in Seoul, South Korea) | 31-Mar-2020 | Corporate Asset Purchase | Buildings and Property |
CJ Bioscience ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Software & Services
Industry
Rank
Percentile
Data Processing
Subindustry
Rank
Percentile
CJ Bioscience FAQs
-
When was CJ Bioscience founded?
CJ Bioscience was founded in 2009.
-
Where is CJ Bioscience headquartered?
CJ Bioscience is headquartered in Seoul, South Korea.
-
What is the size of CJ Bioscience?
CJ Bioscience has 80 total employees.
-
What industry is CJ Bioscience in?
CJ Bioscience’s primary industry is Biotechnology.
-
Is CJ Bioscience a private or public company?
CJ Bioscience is a Public company.
-
What is CJ Bioscience’s stock symbol?
The ticker symbol for CJ Bioscience is 311690.
-
What is the current stock price of CJ Bioscience?
As of 13-Nov-2026 the stock price of CJ Bioscience is $2.66.
-
What is the current market cap of CJ Bioscience?
The current market capitalization of CJ Bioscience is $34.8M.
-
What is CJ Bioscience’s current revenue?
The trailing twelve month revenue for CJ Bioscience is $2.53M.
-
Who are CJ Bioscience’s competitors?
Shanghai Medicilon, GenScript, Personalis, Eurofins Genomics Americas, and Pharmaron are some of the 36 competitors of CJ Bioscience.
-
What is CJ Bioscience’s annual earnings per share (EPS)?
CJ Bioscience’s EPS for 12 months was -$1.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
